Plate Nº 19 · recorded October 10, 2026
Health & Medicine ResearchReported finding
GLP-1 Drugs Linked to More Than Tenfold Higher Aspiration Risk During Anesthesia
A UK study of nearly 47,000 surgical patients found GLP-1 receptor agonist users faced more than ten times the odds of pulmonary aspiration during anesthesia. Researchers call for targeted trials to identify risk-mitigation strategies.
By Priya Raman3 min read561 words
In brief
- 2.9% of 47,039 UK surgical patients across 119 sites reported GLP-1 receptor agonist use
- Pulmonary aspiration or regurgitation occurred in 1.41% of GLP-1 RA users versus 0.12% of non-users (odds ratio 11.39)
- Most aspiration events among GLP-1 users occurred during emergence from anesthesia
- Perioperative management of GLP-1 users — including drug cessation and airway handling — varied widely across hospitals
- Study published September 16, 2026 in Anaesthesia (DOI 10.1111/anae.70380) and presented at the Association of Anaesthetists meeting in Liverpool

Patients taking GLP-1 receptor agonists face more than ten times the odds of pulmonary aspiration or regurgitation during anesthesia compared with non-users, according to a UK study of nearly 47,000 adults published September 16 in Anaesthesia.
The research, led by Thomas E. Potter of Guy's and St Thomas' NHS Foundation Trust in London, drew on records from 119 hospitals across the United Kingdom. Of the 47,039 adults who underwent elective or emergency surgery, 2.9% — roughly 1,360 patients — reported using GLP-1 receptor agonists (GLP-1 RAs).
GLP-1 RAs mimic a gut hormone called glucagon-like peptide-1 that lowers blood sugar, curbs appetite, and slows the movement of food from the stomach into the intestines. The class includes semaglutide (brands Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). Their delay of gastric emptying has long made anesthesiologists wary that residual stomach contents could enter the lungs during or after surgery.
How big was the risk gap?
In the GLP-1 RA group, pulmonary aspiration or regurgitation occurred in 1.41% of cases, compared with 0.12% in the non-user group. That difference corresponds to an odds ratio of 11.39 — close to an order-of-magnitude increase.
Pulmonary aspiration is uncommon but dangerous. When stomach contents reach the lungs, they can cause choking, breathing difficulties, or aspiration pneumonia, and the most severe cases may be fatal. In routine surgical populations, anesthesiologists generally cite rates below one in a thousand, roughly matching the 0.12% figure this study found among non-users.
When did the events happen?
Most aspiration or regurgitation episodes struck GLP-1 RA patients during emergence from anesthesia — the wake-up phase after the procedure — rather than when anesthetic drugs were first administered. The study did not collect matching timing for non-users, so the team could not directly compare timing between groups.
How did hospitals manage GLP-1 users?
Perioperative care varied considerably across the 119 sites. Some clinicians continued the drugs up to surgery; others paused them days in advance. Airway-management choices also differed. The authors flagged that variability as a finding in itself, because no single standard of care has yet emerged for this fast-growing patient group.
What does the study not yet prove?
The design was observational, so it identified an association rather than a cause. Patient weight, type of surgery, diabetes status, or differences in how anesthesiologists approached the airway could also contribute to the gap. Potter's team argues that further prospective trials would be needed to test specific risk-reduction strategies — for example, extended preoperative fasting, ultrasound exams of the stomach, or modified airway protocols.
"These data warrant further prospective studies to determine interventions that may mitigate risks of pulmonary aspiration and improve patient outcomes," the authors wrote.
What should patients and clinicians do now?
Existing anesthesia-society guidance generally recommends pausing GLP-1 medications before elective procedures, though the exact interval and the role of stomach ultrasound remain debated. The new findings reinforce that caution but offer no single recipe. Patients scheduled for surgery should review their GLP-1 use with the anesthesiology team, since management plans can change depending on the drug, dose, and procedure.
The work appeared alongside the Association of Anaesthetists' annual meeting, held September 16–18 in Liverpool, England. Its DOI is 10.1111/anae.70380.
via Medical Xpress (Source)
More from Priya Raman
Show full bio
Senior reporter covering industry trends and analytics at SciBeat.
207 articles
Nearby plates
- Cleveland Clinic Examines What Happens After GLP-1 Discontinuation
- Semaglutide and Tirzepatide: Heart Outcomes Compared in Real-World Study
- Quitting Ozempic for Two Years Raises Heart Risk by 22%
- Semaglutide Linked to 21% Lower Psychiatric Hospitalization Risk
- GLP-1 Diabetes Drugs Appear Safe in Pregnancy, Review Finds